Becton, Dickinson and Company $BDX Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 25,108 shares of the medical instruments supplier’s stock after purchasing an additional 3,127 shares during the quarter. Public Sector Pension Investment Board’s holdings in Becton, Dickinson and Company were worth $4,699,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after purchasing an additional 4,305,947 shares during the last quarter. Norges Bank bought a new position in Becton, Dickinson and Company during the 2nd quarter worth $653,377,000. First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Becton, Dickinson and Company by 24.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after buying an additional 1,670,590 shares during the last quarter. Finally, Laurel Wealth Advisors LLC grew its position in shares of Becton, Dickinson and Company by 16,974.4% during the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock worth $272,049,000 after acquiring an additional 1,570,136 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX opened at $182.29 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $185.02. The company has a market capitalization of $51.91 billion, a price-to-earnings ratio of 29.74, a price-to-earnings-growth ratio of 13.24 and a beta of 0.25. The business has a 50 day moving average price of $197.64 and a two-hundred day moving average price of $192.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the business earned $3.43 EPS. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,416 shares of company stock worth $675,557 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BDX. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. TD Cowen boosted their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Barclays assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Finally, Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.